Evonik Venture Capital GmbH

What they fund

• Stage — Seed to Series B, with a strong emphasis on Series A and Series B. [2], - Sector — Deep Tech, Industrial, Climate & Energy, Health, and Digitalization (AI, IoT, Big Data). [1][2], - Geography — Germany, USA, and China, with a global reach. [1], - Check Size — Up to €15 million per portfolio company, with a typical range of €0 - €15 million. [1][2]

Investment thesis

Evonik Venture Capital (EVC) partners with entrepreneurs developing breakthrough technologies that complement Evonik Industries’ core competencies in specialty chemicals, pharmaceuticals and advanced manufacturing. [1] The firm focuses on solutions that enable sustainable production, resource efficiency and digital transformation across the chemical value chain. [1] By providing capital, industry expertise and access to Evonik’s global R&D network, EVC aims to accelerate commercialization of innovations that can create new market opportunities for both the startup and its corporate parent. [1]

• Strategic alignment — Investments target Evonik's growth fields: Advance Precision Biosolutions, Energiewende (energy transition), and Circular Economy. [2]
• Sector focus — Deep Tech, Industrial, Climate & Energy, Health, and Digitalization (AI, IoT, Big Data). [1][2]
• Value creation — Startups gain access to Evonik's network of potential customers, technology experts, and business partners, alongside strategic, technical, and commercial expertise. [1]
• Global reach — Offices in Germany, USA, and China enable investment in innovative technologies across key regions. [1]

Credibility: The thesis is derived from EVC's public profile on Gilion [1], VCGermany [2], and Waveup [3], which consistently highlight the strategic partnership with Evonik, focus on sustainability/deep tech, and access to corporate resources.

Interconnection: The focus on Deep Tech and Industrial sectors directly informs the typical ticket size and stage, as these require significant capital and technical validation before Series A/B.

Value add

EVC provides strategic, technical, and commercial support, leveraging its extensive network for the growth of portfolio companies. [3] Startups gain access to Evonik's network of potential customers, technology experts, and business partners. [1]

Fit verdict: Ideal for deep tech and industrial startups requiring technical validation and access to a large chemical/pharma corporation's supply chain and R&D capabilities.

Founder diligence script:

• How does EVC facilitate introductions to Evonik's specific business lines (e.g., Nutrition & Care, Smart Materials)? [1]
• What is the typical timeline for technical validation and commercial pilot programs with Evonik? [1]
• How does EVC structure follow-on investments, and what is the historical follow-on rate? [2]
• What level of board involvement or advisory role does EVC typically take in Series A/B rounds? [4]

Portfolio focus

• Health/Biotech — Allay Therapeutics (post-surgery pain relief implant), Biograil (Series A, €8.5M, 2025), Abolis Biotechnologies (Series B, €35M, 2024). [2], - Materials & Sustainability — Interface Polymers (additives for easier recycling of plastics), SuperC (graphene materials for lithium-ion batteries). [3], - Digital/AI — Citrine Informatics (AI-driven platform for materials and chemicals development). [3]

Notable investments & exits

• Exits — EVC has 11+ exits, but specific names and outcomes are not publicly detailed in the provided documents. [2], - Losses — No specific information on losses is publicly disclosed. [1]

Strategic implications

EVC's €400M fund size and 11+ exits demonstrate a mature, well-capitalized corporate VC arm capable of significant impact. [1][2] Its focus on Deep Tech and Industrial sectors aligns with Evonik's strategic growth fields, creating a strong moat for portfolio companies in terms of technical validation and market access. [2] The main risk is the potential for strategic misalignment if Evonik's corporate priorities shift, which could impact follow-on support or exit opportunities. [1] A signal that would change the read is a significant reduction in EVC's deployment rate or a shift in focus away from Deep Tech/Industrial sectors, indicating a potential retreat from strategic innovation. [2]

EVC's global offices (Germany, USA, China) provide a unique advantage for startups seeking international expansion and access to diverse supply chains. [1] This global footprint is a key differentiator compared to regional corporate VCs. [1] The firm's ability to leverage Evonik's R&D network is a critical value-add for biotech and materials science startups. [3]

The 11+ exits suggest a disciplined approach to value creation and exit planning, which is crucial for corporate VC arms. [2] This track record enhances EVC's credibility with limited partners and portfolio companies. [1]

Where they could go further

EVC could enhance its transparency by publishing more detailed case studies on its exits and follow-on investments, providing clearer signals to the startup community about its value creation process. [2], Expanding its focus to include more early-stage (pre-seed/seed) investments could help EVC capture emerging technologies earlier in their lifecycle, securing better entry valuations and deeper strategic alignment. [1], EVC could strengthen its network effects by organizing more industry-specific events or workshops that connect portfolio companies with Evonik's business lines and external partners, fostering collaboration and innovation. [1], Publishing a more detailed investment thesis or sector-specific reports would help startups better understand EVC's strategic priorities and increase the quality of inbound deal flow. [2]